Previous 10 | Next 10 |
Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference PR Newswire BOSTON and AT...
Inhibikase Therapeutics Inc. (NASDAQ:IKT) traded at a new 52-week high today of $11.80. This new high was reached on above average trading volume as 11.5 million shares traded hands, while the average 30-day volume is approximately 94,000 shares. Inhibikase Therapeutics Inc is a clinical...
Inhibikase Therapeutics to Host Virtual KOL Investor Event on April 20, 2022 PR Newswire BOSTON and ATLANTA , April 6, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company de...
Inhibikase Therapeutics, Inc. (IKT) Q4 2021 Results Conference Call April 1, 2022 08:00 AM ET Company Participants Alexander Lobo - Stern Investor Relations Dr. Milton Werner - Chief Executive Officer Joseph Frattaroli - Chief Financial Officer Presentation Operator Greetings, welcome to Inhi...
Inhibikase Therapeutics press release (NASDAQ:IKT): FY GAAP EPS of -$0.81. Revenue of $3.1M (+342.9% Y/Y). For further details see: Inhibikase Therapeutics GAAP EPS of -$0.81, revenue of $3.1M
Inhibikase Therapeutics Reports Full Year 2021 Financial Results and Highlights Recent Period Activity PR Newswire BOSTON and ATLANTA , March 31, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stag...
Inhibikase Therapeutics to Participate in the Next Generation Kinase Inhibitors Summit PR Newswire BOSTON and ATLANTA , March 28, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical compan...
Inhibikase Therapeutics to Report Full Year 2021 Financial Results on March 31, 2022 PR Newswire BOSTON and ATLANTA , Mar. 25, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing t...
Inhibikase Therapeutics to Participate in the Maxim Group 2022 Virtual Growth Conference PR Newswire BOSTON and ATLANTA , March 23, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company ...
Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD™ Alzheimer's & Parkinson's Diseases Conference Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD™ Alzheimer's & Parkinson's Diseases Conference...
News, Short Squeeze, Breakout and More Instantly...
Inhibikase Therapeutics Inc. Company Name:
IKT Stock Symbol:
NASDAQ Market:
Inhibikase Therapeutics Inc. Website:
BOSTON and ATLANTA, June 17, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinso...
- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kin...
BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson...